
ChemoCentryx CCXI
Quarterly report 2022-Q2
added 08-08-2022
ChemoCentryx General and Administrative Expenses 2011-2026 | CCXI
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses ChemoCentryx
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 78.9 M | 42.2 M | 24.2 M | 20.4 M | 16.5 M | 14.7 M | 14.5 M | 13.6 M | 11.6 M | 10.5 M | 7.62 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 78.9 M | 7.62 M | 23.1 M |
Quarterly General and Administrative Expenses ChemoCentryx
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 28.2 M | 26 M | - | 19.6 M | 19.7 M | 16.3 M | - | 10.4 M | 10.3 M | 8.82 M | - | 6.12 M | 5.57 M | 5.5 M | - | 5.37 M | 4.75 M | 4.66 M | - | 3.62 M | 4.18 M | 4.57 M | - | 3.19 M | 3.88 M | 4.08 M | - | 3.81 M | 3.58 M | 3.69 M | - | 3.51 M | 3.38 M | 3.52 M | - | 2.88 M | 2.81 M | 2.96 M | - | 2.62 M | 2.47 M | 2.56 M | - | 1.77 M | 1.94 M | 2.01 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.2 M | 1.77 M | 6.81 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Immatics N.V.
IMTX
|
33.8 M | $ 9.4 | -1.16 % | $ 591 M | ||
|
Incyte Corporation
INCY
|
1.38 B | $ 90.47 | 0.02 % | $ 17.7 B | ||
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
Aileron Therapeutics
ALRN
|
13.9 M | - | 10.36 % | $ 9.8 M | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
160 M | $ 215.49 | -1.18 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 19.43 | 1.04 % | $ 908 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | ||
|
CytomX Therapeutics
CTMX
|
29.8 M | $ 4.19 | -5.95 % | $ 578 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
5.94 M | $ 0.72 | 18.96 % | $ 8.25 M | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
Exelixis
EXEL
|
519 M | $ 41.39 | -0.05 % | $ 11.2 B | ||
|
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
46.7 M | $ 1.35 | -3.57 % | $ 344 M | ||
|
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
17.4 M | $ 2.59 | -1.52 % | $ 16.3 M | ||
|
Atreca
BCEL
|
31.5 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B | ||
|
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
15.9 M | $ 4.29 | -3.05 % | $ 822 M | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Ionis Pharmaceuticals
IONS
|
394 M | $ 69.54 | -1.77 % | $ 11.1 B | ||
|
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | ||
|
Calithera Biosciences
CALA
|
20.9 M | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
Cara Therapeutics
CARA
|
27.8 M | - | -3.03 % | $ 260 M | ||
|
Harmony Biosciences Holdings
HRMY
|
153 M | $ 27.01 | -2.14 % | $ 1.55 B | ||
|
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K |